thiophenes has been researched along with volasertib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yim, H | 1 |
| Abbott, NJ; Bertone, P; Danovi, D; Elbatsh, AM; Ender, C; Engström, PG; Ferretti, P; Folarin, A; Gagrica, S; Georgian, A; Gogolok, S; Harvey, KJ; Paddison, PJ; Pollard, SM; Preston, JE; Smith, A; Stricker, SH; U, KP; Yu, D | 1 |
| Bogado, RF; Brassesco, MS; de Oliveira, HF; Pezuk, JA; Tone, LG | 1 |
| Althoff, K; Dreesmann, S; Eggert, A; Schramm, A; Schulte, JH; Schwermer, M; Steenpass, L; Temming, P | 1 |
| Frederick, M; Johnson, FM; Kalu, NN; Li, L; Mazumdar, T; Myers, JN; Peng, S; Pickering, CR; Sambandam, V; Shen, L; Singh, R; Tong, P; Wang, J; Zhang, M | 1 |
| Brassesco, MS; Pezuk, JA; Roberto, GM; Salomão, KB; Scrideli, CA; Tone, LG | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
| Jang, HR; Kim, CH; Shin, SB; Yim, H | 1 |
1 review(s) available for thiophenes and volasertib
| Article | Year |
|---|---|
Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes | 2013 |
7 other study(ies) available for thiophenes and volasertib
| Article | Year |
|---|---|
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
Topics: Animals; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indans; Mice; Mice, Knockout; Neoplastic Stem Cells; Neural Stem Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Small Molecule Libraries; Swine; Thiophenes; Tumor Suppressor Protein p53 | 2013 |
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Osteosarcoma; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes | 2015 |
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinases; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Phosphorylation; Polo-Like Kinase 1; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Real-Time Polymerase Chain Reaction; Retinal Neoplasms; Retinoblastoma; Thiophenes; Tumor Cells, Cultured | 2017 |
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genotype; Head and Neck Neoplasms; Humans; LIM Domain Proteins; Mice, Nude; Molecular Targeted Therapy; Mutation; Nuclear Proteins; Phenotype; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; ras Proteins; RNA Interference; Signal Transduction; Smad4 Protein; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Time Factors; Transfection; Tumor Burden; Urea; Xenograft Model Antitumor Assays | 2017 |
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents; Thiophenes | 2018 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
Topics: A549 Cells; Cell Cycle Proteins; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes; Ubiquitin-Specific Peptidase 7 | 2020 |